TORONTO, CANADA / ACCESSWIRE / November 26, 2018 / Vanadium One Energy Corp. (TSX-V: VONE), continues to strengthen its Board of Directors and management team with the appointment of two industry leaders to its Board of Directors. The Company is please to announce that Mr. Mark Brennan and Mr. Casper Groenewald have joined the Board of Directors and Mr. Brennan will become the Company’s first Chairman. Messrs. Brendan and Groenewald were instrumental in building Largo Resources and its Maracas Menchen Mine. They lead an impressive slate of proposed Directors for election at the Company’s next AGM, to be held on December 18, 2018.
Month: November 2018
TORONTO, Nov. 26, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (Nasdaq: GWPH) in the United Kingdom. In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom, which will support FSD Pharma’s strategy of expanding its global footprint. Interim CEO and Co-chairman of the board, Dr. Raza Bokhari will remain in place as CEO until Mr. Haynes officially assumes the role.
TORONTO, Nov. 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors.
TORONTO, Nov. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations.
VANCOUVER, British Columbia, Nov. 09, 2018 (GLOBE NEWSWIRE) — Mission Ready Solutions Inc. (“Mission Ready” or the “Company”) (TSXV:MRS) wishes to provide a general update on the Company’s progress, including (i) the non-binding letter of intent to acquire (the “Acquisition”) Unifire, Inc.; (ii) the engagement letter (the “Engagement Letter”) with Bay Crest Partners, LLC (the “Agent”); (iii) the fee agreement (the “Fee Agreement”) with Celadon Financial Group, LLC (“Celadon”); and (iv) the Foreign Military Distribution Agreement (the “Distribution Agreement”) first announced on September 6, 2017, with subsequent related announcements provided on September 20, 2017, November 30, 2017, and December 29, 2017.
TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) — Canada House Clinics, the clinic division of Canada House Wellness Group Inc (“Canada House” or the “Company”) (CSE: CHV), is pleased to announce it has entered into a strategic partnership with Peak Pharma Solutions, leveraging its new clinic branding and organizational changes to position itself for accelerated growth.
1933 Industries Inc. (CSE:TGIF, FWB:1QF, OTC:VPGDF) (the “Company” or “1933 Industries”) a licensed cultivator and producer of cannabis flower and concentrates and manufacturer of hemp/CBD wellness products, is pleased to provide an update regarding its expansion projects in Las Vegas, Nevada.
NuRAN Wireless Inc. (CSE:NUR,FWB:1RN,OTCMKTS:NRRWF), a leading supplier of mobile and broadband wireless infrastructure solutions is pleased to announce that it has secured a long term low interest loan facility of up to $3M CAD with the Quebec Government and its ‘Creativite Quebec’ program.
MISSISSAUGA, ON, Nov. 8, 2018 /PRNewswire/ – Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a globally focused, healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced its financial and operational results for the third quarter ended September 30, 2018. For further details on the results, please refer to Nuvo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements which are available on the Company’s website (www.nuvopharmaceuticals.com). All figures are in Canadian dollars, unless otherwise noted.